Bristol-Myers Squibb Company Ce (CELG-RI) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CELG-RI Revenue Growth
Revenue Breakdown (FY 2025)
CELG-RI's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
CELG-RI Revenue Analysis (2014–2025)
As of May 6, 2026, Bristol-Myers Squibb Company Ce (CELG-RI) generated trailing twelve-month (TTM) revenue of $48.48 billion, reflecting modest growth of +2.6% year-over-year. The most recent quarter (Q1 2026) recorded $11.49 billion in revenue, down 8.1% sequentially.
Looking at the longer-term picture, CELG-RI's 5-year compound annual growth rate (CAGR) stands at +2.5%, indicating moderate growth over time. The company achieved its highest annual revenue of $48.30 billion in 2024.
Revenue diversification analysis shows CELG-RI's business is primarily driven by Eliquis (30%), Opdivo (21%), and Orencia (8%).
When compared to Healthcare sector peers including BMY (+1.8% YoY), MRK (+1.2% YoY), and PFE (+1.4% YoY), CELG-RI has underperformed the peer group in terms of revenue growth. Compare CELG-RI vs BMY →
CELG-RI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CELG-RICurrent | $48.5B | +2.6% | +2.5% | 31.4% | |
 BMY | $48.2B | +1.8% | +2.5% | 26.3% | |
 MRK | $64.9B | +1.2% | +9.4% | 36.2% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 AZN | $58.7B | +9.9% | +17.2% | 23.4% | |
 LLY | $65.2B | +47.4% | +21.6% | 45.6% |
CELG-RI Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $48.19B | -0.2% | $31.76B | 65.9% | $15.12B | 31.4% |
| 2024 | $48.30B | +7.3% | $27.43B | 56.8% | $9.66B | 20.0% |
| 2023 | $45.01B | -2.5% | $34.31B | 76.2% | $8.20B | 18.2% |
| 2022 | $46.16B | -0.5% | $36.02B | 78.0% | $9.10B | 19.7% |
| 2021 | $46.38B | +9.1% | $36.45B | 78.6% | $8.54B | 18.4% |
| 2020 | $42.52B | +62.6% | $30.75B | 72.3% | $2.18B | 5.1% |
| 2019 | $26.14B | +15.9% | $18.07B | 69.1% | $5.91B | 22.6% |
| 2018 | $22.56B | +8.6% | $16.01B | 71.0% | $5.12B | 22.7% |
| 2017 | $20.78B | +6.9% | $14.71B | 70.8% | $3.45B | 16.6% |
| 2016 | $19.43B | +17.3% | $14.48B | 74.5% | $4.54B | 23.4% |
See CELG-RI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CELG-RI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CELG-RI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCELG-RI — Frequently Asked Questions
Quick answers to the most common questions about buying CELG-RI stock.
Is CELG-RI's revenue growth accelerating or slowing?
CELG-RI revenue growth slowed to +2.6%, below the 5-year CAGR of +2.5%. TTM revenue is $48.5B. The deceleration marks a shift from historical growth rates.
What is CELG-RI's long-term revenue growth rate?
Bristol-Myers Squibb Company Ce's 5-year revenue CAGR of +2.5% reflects the variable expansion pattern. Current YoY growth of +2.6% is near this long-term average.
How is CELG-RI's revenue distributed by segment?
CELG-RI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.